Quality Improvement in Diabetes Care: A Review of Initiatives and Outcomes in the T1D Exchange Quality Improvement Collaborative.
| Autor: | Ginnard OZB; Texas Children's Hospital, Houston, TX., Alonso GT; Barbara Davis Center, University of Colorado, Aurora, CO., Corathers SD; Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH., Demeterco-Berggren C; Rady Children's Hospital, University of California, San Diego, CA., Golden LH; NYU Langone Health, New York, NY., Miyazaki BT; Children's Hospital Los Angeles, Los Angeles, CA., Nelson G; Le Bonheur Children's Hospital, Memphis, TN., Ospelt E; T1D Exchange, Boston, MA., Ebekozien O; T1D Exchange, Boston, MA., Lee JM; Pediatric Endocrinology, University of Michigan, Ann Arbor, MI., Obrynba KS; Nationwide Children's Hospital, The Ohio State University, Columbus, OH., DeSalvo DJ; Texas Children's Hospital, Houston, TX. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical diabetes : a publication of the American Diabetes Association [Clin Diabetes] 2021 Jul; Vol. 39 (3), pp. 256-263. |
| DOI: | 10.2337/cd21-0029 |
| Abstrakt: | Despite immense strides in therapeutic advances, clinical outcomes continue to be less than ideal for people with type 1 diabetes. This discrepancy has prompted an outpouring of quality improvement (QI) initiatives to address the medical, psychosocial, and health equity challenges that complicate ideal type 1 diabetes care and outcomes. This article reviews a framework for QI in diabetes care that guided the development of the T1D Exchange Quality Improvement Collaborative to improve care delivery and health outcomes in type 1 diabetes. Evaluation of the methodology, outcomes, and knowledge gained from these initiatives will highlight the importance of continued QI initiatives in diabetes care. Competing Interests: O.E. is a compensated Health Equity Advisory Board member for Medtronic Diabetes and serves as the principal investigator for investigator-led projects sponsored by Abbott, Dexcom, Eli Lilly, Insulet, and Medtronic. J.M.L. is on the medical advisory board for GoodRx. D.J.D. is a consultant to Dexcom and Insulet. No other potential conflicts of interest relevant to this article were reported. (© 2021 by the American Diabetes Association.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|